sipatrigine has been researched along with glutamic acid in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daly, D; Durant, GJ; Fischer, JB; Goldin, SM; Hu, LY; Knapp, AG; Magar, S; Reddy, NL; Sharma, R; Subbarao, K | 1 |
| Lekieffre, D; Meldrum, BS; Smith, SE; Sowinski, P | 1 |
| Sharp, FR; Swanson, RA | 1 |
| Chen, J; Graham, SH; Lan, J; Leach, MJ; Simon, RP | 1 |
| Meldrum, BS | 1 |
| Bullock, R; Harms, JF; Tsuchida, E; Woodward, JJ | 1 |
| Alp, MS; Aspey, BS; Harrison, MJ; Patel, Y | 1 |
3 review(s) available for sipatrigine and glutamic acid
| Article | Year |
|---|---|
Neuroprotective use-dependent blockers of Na+ and Ca2+ channels controlling presynaptic release of glutamate.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; CHO Cells; Cricetinae; Electrophysiology; Glutamic Acid; Guanidines; Heart Rate; Ischemic Attack, Transient; Kinetics; Neuroprotective Agents; Neurotransmitter Uptake Inhibitors; Piperazines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Recombinant Proteins; Sodium Channel Blockers; Sodium Channels | 1995 |
The role of glutamate in epilepsy and other CNS disorders.
Topics: Animals; Central Nervous System Diseases; Epilepsy; Glutamic Acid; Humans; Lamotrigine; Mice; N-Methylaspartate; Parkinson Disease; Piperazines; Pyrimidines; Rats; Receptors, AMPA; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Sodium Channels; Triazines | 1994 |
Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors | 1997 |
4 other study(ies) available for sipatrigine and glutamic acid
| Article | Year |
|---|---|
Cerebroprotective effect of BW619C89 after focal or global cerebral ischaemia in the rat.
Topics: Animals; Brain Ischemia; Carotid Artery, Common; Cerebral Arteries; Cerebral Infarction; Female; Glutamates; Glutamic Acid; Hippocampus; Male; Neurotransmitter Uptake Inhibitors; Piperazines; Pyrimidines; Rats; Rats, Inbred F344 | 1993 |
BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage.
Topics: Brain Ischemia; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Piperazines; Pyrimidines | 1994 |
Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion.
Topics: Animals; Brain; Brain Ischemia; Glutamates; Glutamic Acid; Ion Channel Gating; Male; Neurotransmitter Uptake Inhibitors; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers | 1994 |
A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat.
Topics: Animals; Aspartic Acid; Brain Ischemia; Dialysis; Disease Models, Animal; Glutamic Acid; Hematoma, Subdural; Male; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sodium Channel Blockers; Threonine | 1996 |